What to do if Cosentyx (secukinumab) isn’t working after 3 months?
Cosentyx can take time to show full effect, but lack of improvement by 12 weeks is still something to act on. The next step is usually a structured check with the prescriber to confirm (1) the diagnosis, (2) the dose schedule, (3) adherence and injections, and (4) whether the target joints/skin sites are the right ones to judge response.
Common actions at the 3‑month mark include reviewing:
- Whether you’re on the correct starter and maintenance dosing schedule for your condition (psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis).
- Whether you missed any doses or had delays in dosing due to illness, insurance, or logistics.
- How severe your baseline symptoms were and whether you and your clinician are using a consistent measure of response (for example, joint counts in arthritis, or body-area estimates for skin).
If you’re getting partial relief, clinicians often consider whether to continue longer versus adjust. If there’s no meaningful response, your prescriber may discuss switching within the same class or a different mechanism depending on your disease type and pattern of symptoms.
Could the diagnosis be the reason it seems to not be working?
“Not working” after 3 months can happen when symptoms are driven by something other than the condition Cosentyx is treating, or when there are overlapping issues. Examples include:
- The symptoms might be from a different inflammatory arthritis, tendon problem, or mechanical pain.
- Skin might be driven by a non-psoriatic rash condition.
- Pain could be partly from longstanding joint damage or degenerative disease, with Cosentyx not fully addressing that component.
A reassessment may include repeat exam, review of imaging/labs (as appropriate), and checking whether the pattern fits what Cosentyx typically improves.
Is 3 months too soon—how long do people usually take to respond?
Many patients start to notice improvement earlier than 12 weeks, but full response timing varies by condition and by whether symptoms are mostly skin, mostly joints, or both. For some, benefits continue building beyond 3 months. Your clinician’s role at this stage is to decide whether your progress rate is within an acceptable range for continued treatment or whether a change is needed.
What if you have side effects but also feel it isn’t working?
If you have adverse effects (even if you also feel minimal benefit), tell your prescriber promptly. Treatment decisions may change if side effects are significant, especially infections, worsening symptoms, or any safety concerns your clinician flags. Don’t stop or change dosing on your own, but do report both symptom status and side effects so the plan can be adjusted safely.
What else can be changed besides switching Cosentyx?
Depending on your condition, clinicians may adjust the overall treatment plan alongside (or instead of) changing the biologic. That can include:
- Optimizing pain management and physical therapy so you can evaluate inflammatory symptoms more clearly.
- Adjusting background medications if you were prescribed them (for psoriatic arthritis, some patients use additional drugs alongside biologics).
- Checking whether an infection or another trigger is keeping symptoms active.
Are there antibody or treatment-resistance issues?
Biologic therapies can sometimes become less effective over time for individual reasons. At 3 months, true “loss of response” is less common than other causes (missed doses, incorrect dosing schedule, misattributed symptoms, or diagnosis mismatch). Still, if the pattern suggests inadequate response, your clinician may consider drug level/antibody testing where available to guide whether to keep, dose-adjust, or switch.
What should you ask your doctor at the next visit?
Bring specific, measurable details:
- When you started Cosentyx and your exact dosing schedule.
- Whether you ever missed doses or delayed injections.
- Where symptoms are worst now versus at baseline.
- What you expected to improve (skin, joints, enthesitis, back pain, fatigue) and how much has changed.
- Any infections or side effects you’ve had since starting.
These details help your clinician decide whether to continue longer, adjust the plan, or switch treatments.
Treatment alternatives: who makes Cosentyx and what other options exist?
Cosentyx is made by Novartis. If your doctor decides to switch, the next options depend on your specific diagnosis (psoriasis vs psoriatic arthritis vs axial spondyloarthritis) and your response profile. Your prescriber will choose among other biologics or targeted therapies that match your disease domain (skin-heavy, joint-heavy, or axial disease).
For background on patents and commercial landscape around secukinumab, DrugPatentWatch.com can be a helpful reference: https://www.drugpatentwatch.com/ (search for Cosentyx/secukinumab there).
---
If you tell me which condition you’re using Cosentyx for (psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis) and what “not working” means for you (skin vs joint vs back pain, and how much it has improved), I can narrow down what clinicians typically check at the 3‑month point and what kinds of next steps are most common.
Sources:
1. DrugPatentWatch.com